Combination treatment with vedolizumab and anti-TNF-α in inflammatory bowel disease: safety data

被引：0
|
作者：
Buer, L. [1 ,2 ]
Hoivik, M. L. [1 ]
Medhus, A. W. [1 ]
Moum, B. [1 ,2 ]
机构：
[1] Oslo Univ Hosp, Dept Gastroenterol, Oslo, Norway
[2] Univ Oslo, Inst Clin Med, Oslo, Norway
来源：
JOURNAL OF CROHNS & COLITIS | 2017年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P514
引用
收藏
页码：S341 / S342
页数：2
相关论文
共 50 条
  • [31] Remission state in Inflammatory Bowel Disease patients on anti TNF or vedolizumab: a confocal endomicroscopy study
    Loly, J. P.
    Vieujean, S.
    Reenaers, C.
    Van Kemseke, C.
    Seidel, L.
    Somja, J.
    Louis, E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I283 - I283
  • [32] ANTI-TNF EFFICACY AFTER PRIMARY VEDOLIZUMAB FAILURE IN PEDIATRIC INFLAMMATORY BOWEL DISEASE
    Dolinger, Michael
    Rolfes, Priya
    Phan, Becky
    Pan, Stephanie
    Dubinsky, Marla
    GASTROENTEROLOGY, 2020, 158 (03) : S116 - S116
  • [33] Effectiveness and Safety of Vedolizumab in Anti-TNF-Naive Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study
    Kopylov, Uri
    Verstockt, Bram
    Biedermann, Luc
    Sebastian, Shaji
    Pugliese, Daniela
    Sonnenberg, Elena
    Steinhagen, Peter
    Arebi, Naila
    Ron, Yulia
    Kucharzik, Torsten
    Roblin, Xavier
    Ungar, Bella
    Shitrit, Ariella Bar-Gil
    Ardizzone, Sandro
    Molander, Pauliina
    Coletta, Marina
    Peyrin-Biroulet, Laurent
    Bossuyt, Peter
    Avni-Biron, Irit
    Tsoukali, Emmanouela
    Allocca, Mariangela
    Katsanos, Konstantinos
    Raine, Tim
    Sipponen, Taina
    Fiorino, Gionata
    Ben-Horin, Shomron
    Eliakim, Rami
    Armuzzi, Alessandro
    Siegmund, Britta
    Baumgart, Daniel C.
    Kamperidis, Nikolaos
    Maharshak, Nitsan
    Maaser, Christian
    Mantzaris, Gerassimos
    Yanai, Henit
    Christodoulou, Dimitrious K.
    Dotan, Iris
    Ferrante, Marc
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (11) : 2442 - 2451
  • [34] Influence of the interval of time between anti-TNF and vedolizumab or ustekinumab in the response to treatment in patients with inflammatory bowel disease
    Baston Rey, I.
    Costa, M.
    Calvino-Suarez, C.
    Mauriz-Barreiro, V.
    De la Iglesia, D.
    Gonzalez, J.
    Ferreiro-Iglesias, R.
    Dominguez-Munoz, J. E.
    Barreiro-de Acosta, M.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S539 - S539
  • [35] Optimizing anti-TNF treatment in inflammatory bowel disease
    Rutgeerts, P
    Van Assche, G
    Vermeire, S
    GASTROENTEROLOGY, 2004, 126 (06) : 1593 - 1610
  • [36] Safety of anti-TNF biologics in paediatric inflammatory bowel disease
    Ruemmele, Frank M.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (11): : 813 - 815
  • [37] Accelerating Earlier Access to Anti-TNF-α Agents with Biosimilar Medicines in the Management of Inflammatory Bowel Disease
    Fiorino, Gionata
    Ananthakrishnan, Ashwin
    Cohen, Russell D.
    Cross, Raymond K.
    Deepak, Parakkal
    Farraye, Francis A.
    Halfvarson, Jonas
    Steinhart, A. Hillary
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (05)
  • [38] A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy
    Fonseca Chebli, Julio Maria
    Gaburri, Pedro Duarte
    Chebli, Liliana Andrade
    da Rocha Ribeiro, Tarsila Campanha
    Tavares Pinto, Andre Luiz
    Ambrogini Junior, Orlando
    Mourao Cintra Damiao, Aderson Omar
    MEDICAL SCIENCE MONITOR, 2014, 20 : 487 - 498
  • [39] Regional differences in anti-TNF- therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study
    Lirhus, Sandre Svatun
    Hoivik, Marte Lie
    Moum, Bjorn
    Melberg, Hans Olav
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2018, 53 (08) : 952 - 957
  • [40] Treatment of inflammatory bowel disease patients with anti-TNF-α factors and immunosuppressives does not influence the prevalence of Helicobacter pylori infection
    John K. Triantafillidis
    Aristofanis Gikas
    Emmanuel Merikas
    Indian Journal of Gastroenterology, 2014, 33 (4) : 383 - 384
12345